Antibody response rates in patients with CLL after 2 doses of COVID-19 vaccine. (A) Response rates by treatment history. TN patients had a response rate of 72% (151 of 210), significantly higher than that of previously treated patients (60%; 78 of 130; P = .02) and patients receiving therapy (22%; 36 of 166; P < .001). (B) Response rates for patients receiving therapy (n = 166) by treatment type. Patients receiving venetoclax monotherapy had a significantly higher response rate (52%; 12 of 23) than patients who were treated with BTKi’s (22%; 23 of 104; P < .001). All patients treated with venetoclax plus anti-CD20 mAb’s (n = 19) and venetoclax plus BTKi’s (n = 6) were seronegative after the second dose of vaccine. *P < .01; **P < .001; ***P < .0001.